Peregrine Asset Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Peregrine Asset Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,000	Closed	-$219K	–	155
2020 Q4	$219K	Hold	3,000	–	–	0.1%	116
2020 Q3	$233K	Buy	+3,000	New	+$206K	0.13%	89
2016 Q4	–	Sell	-154,704	Closed	-$2.81M	–	126
2016 Q3	$2.81M	Buy	+154,704	New	+$3.02M	1.77%	25

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Peregrine Asset Advisers's HZNP Position: Q1 2021 in Review

Peregrine Asset Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 3,000 shares — an estimated $219K sold.

Peregrine Asset Advisers first reported a position in HZNP in Q3 2016 and held it in 3 quarters. The position peaked at $2.81M in Q3 2016. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

Peregrine Asset Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
Peregrine Asset Advisers sold 3,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $219K.
Peregrine Asset Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 3 quarters.
Peregrine Asset Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.81M in Q3 2016.
516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Peregrine Asset Advisers's 13F filing for Q1 2021, filed 13 May 2021.